NeoImmuneTech, Inc. (KOSDAQ:950220)

Market Cap	256.07B -49.6%
Revenue (ttm)	1.76B +744.1%
Net Income	-24.45B
EPS	-196.21
Shares Out	98.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	838,131
Open	2,505.00
Previous Close	2,505.00
Day's Range	2,475.00 - 2,650.00
52-Week Range	1,115.00 - 5,465.00
Beta	0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2026

About NeoImmuneTech

NeoImmuneTech, Inc., a clinical-stage T cell-based biotechnology company, develops and sells immuno-therapeutics in Korea. It is developing NT-I7, an IL-7 class T- cell amplifier to treat acute radiation syndrome; and Heterodimer hybrid Fc platform, an antibody platform technology, as well as NT2020, a T cell activator; NT3020, a T cell engager; NT4010, an advanced CAR-T; and NT5010, a TME modifier. The company was incorporated in 2014 and is headquartered in Rockville, Maryland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 52
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950220

Financial Performance

In 2025, NeoImmuneTech's revenue was 94.82 million, a decrease of -44.35% compared to the previous year's 170.38 million. Losses were -31.80 billion, -22.23% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 1, 2026

Data Sources Report a data error